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time trade-off for Polish population were used to evaluate inﬂu-
ence of demographic, social and cultural factors on EQ-5D utility
value. Based on additional data concerning demographic and
lifestyle factors collected, adjusted modeling was performed
using GRETL and WinBugs software. Impact of this factors was
analyzed by directly including variables in the model, as well as
adjusting for variables corresponding interaction between the
factors and health domain. RESULTS: Data from 230 interviews
(5280 valuations) were analyzed. Preliminary random effects
model was developed, with constant and N3 factor, all coefﬁ-
cients statistically signiﬁcant, R2 equal to 0.37 and value -0.647
for 33,333 health state. After adjusting base model for gender
and smoking no inﬂuence on utility value was observed. Includ-
ing the interaction terms between age (0–1 variable deﬁned as
above/below median of 38 years) and belief in life after death
(deﬁned as strong agreement) with health domains (level 3)
proved to be statistically signiﬁcant and improved model R2 up to
0.40. Direct inﬂuence of belief in life after death on the utility
value of health states was signiﬁcant, R2 equal to 0.38 and
coefﬁcient value 0.16. CONCLUSIONS: Demographic and cul-
tural factors inﬂuence the utility value of health in Polish popu-
lation. According to results based on preliminary data belief in
life after death signiﬁcantly reduces utility loss.
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OBJECTIVES: Patient-Reported Outcomes (PRO) are routinely
used to measure disease severity, perceived treatment impact, or
patient attitude toward treatment. However, adherence can only
partially be explained by clinical and PRO variables alone. Our
objective is to develop a generic Acceptability measure assessing
how patients balance out between advantages and disadvantages
of long-term treatments. It could be used in future adherence
studies through pharmacies. METHODS: A literature review
was conducted in biomedical databases using keywords related
to acceptability, perceptions, motivations and barriers linked to
treatment. From 434 abstracts reviewed, 29 articles containing
relevant concepts were retained to form the initial conceptual
model of Acceptability. Exploratory interviews were performed
with 5 pharmacists and 18 patients. They were recorded, tran-
scribed word-for-word and systematically analysed. Concepts
captured were organised into a detailed model used as a basis for
the development of the test-version of the Acceptability question-
naire. RESULTS: The initial model of Acceptability included 6
global concepts: treatment perception, disease perception, judge-
ment, behaviour, individual characteristics and medical context.
The pharmacist interviews conﬁrmed this model. The patient
interviews conﬁrmed the inﬂuence of treatment attributes on
their Acceptability, but invalidated the concept of a judgment.
The model adopted for the conceptual content of the Acceptabil-
ity questionnaire covers 23 attributes organised in three major
domains: efﬁcacy, safety and convenience. Patients will be asked
to rate how the treatment suits them, for each of the attributes.
CONCLUSIONS: Qualitative research on Acceptability conﬁrms
the relevance of the concept for patients, but it also shows that
judging whether a drug is good or not is left to the expertise of
the health care professional. Appropriate wording was critical
during item generation to capture the information in a way that
make sense for the patients. After the testing and revision of the
questionnaire, it will be able to be included in adherence studies.
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OBJECTIVES: Treatment Satisfaction (SATMED-Q) is a generic
PRO instrument measuring Treatment satisfaction with medi-
cines in chronic health conditions. Several multisample analysis
are carried out in order to assess the stability of the question-
naire structure across of different types of patients, and to dis-
cover possible differences in dimension correlations for different
drug treated pathologies. METHODS: Four samples of patients
with different known pathologies following regular medication
treatment were gathered from specialized units, and primary
attention centres: hypertensive, drug-refractory-epilepsy sub-
jects, caregivers of patients with dementia of the Alzheimer type
and a normative sample. Exploratory factor analyses on each
separate sample were carried out to assess sample speciﬁc struc-
tures. Multi-sample conﬁrmatory factor analysis was used to
assess the degree of agreement between sample structures using
the known theoretical structure. Congruence statistics were also
used with exploratory structures. RESULTS: A total of 2777
patients were gathered: 1,025 hypertensive patients -47%
women, 63 (11.3) years old-, 768 epileptic patients -65%
women, 41 (13.4) years old-, 842 Alzheimer patients care-
givers -63% women, 78 (6,8) years old-, and the normative
sample used to develop the SATMED-Q composed by 442
patients of different pathologies -50% women, 62 (13.6) years
old-. The theoretical 6-factor solution identiﬁed in the original
instrument was attained in all sample speciﬁc exploratory
analyses. The multi-sample conﬁrmatory analysis matched the
6-dimensional solution but usual goodness of ﬁt problems with
large sample sizes were found. Sample speciﬁc conﬁdence inter-
vals for factor loadings and factor correlations were obtained.
Congruence statistics were reasonable, but were not able to
explain differences in the obliqueness of factors. Meaningful
differences in dimension correlations between samples were
found. CONCLUSIONS: The structure of the SATMED-Q
questionnaire is shown to be stable across different type of
treatments and patients, but the relations between dimensions
vary depending on the pathology studied.
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BACKGROUND: In the last decade various studies have been
published that reported the costs of non-compliance. However,
the quality of those studies has been questioned. OBJECTIVES:
To systematically review and critically appraise the literature to
identify the main methodological limitations related to estimat-
ing and reporting costs of non-compliance in patients with dia-
betes, schizophrenia, rheumatoid arthritis and osteoporosis.
METHODS: A literature review was conducted using PubMed,
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Cochrane Database, EMBASE and CINAHL electronic data-
bases. Studies included were published in the last decade, irre-
spective language that reported data on costs of adherence, non
adherence, or costs by adherence range. Two independent
researchers reviewed the titles and abstracts by disease. A tem-
plate was developed to extract data. Methodological issues were
compared both within and among each disease area. RESULTS:
A total of 145 full manuscripts were identiﬁed: 50 related to
diabetes, 52 to osteoporosis 43 to schizophrenia, and zero to
rheumatoid arthritis. Ten studies for diabetes, six for psychosis
and four for osteoporosis (20 total) were reviewed. Most studies
used cohort designs. Medication possession ratio was the most
common measure of compliance. There was signiﬁcant variation
in how outcomes were reported. Some non-compliance costs
were reported using 5%, 5%–25% and >25% thresholds of
non-compliance. Other studies reported total savings among
compliers, or differential medical charges between compliers and
non-compliers. Further, important differences were found in the
type of clinical and economic outcomes, window period, and
adjustment for confounders not only within disease-speciﬁc
studies but also across studies. CONCLUSIONS: There are sig-
niﬁcant methodological differences in studies of costs of non-
compliance in patients with chronic diseases. Readers should be
aware of those differences when comparing results of a speciﬁc
disease. Better and standardized methodology should be devel-
oped to allow comparison of non-compliance costs.
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OBJECTIVES: To explore whether discrepancies in values for
health states exist between the general population (healthy
people) and people who actually experience illness (patients).
It was hypothesized that the more elementary measurement
methods are, the more similar the responses of patients and
healthy people would be. This means that standardization of
own assessments supplemented with comparative judgment
would largely eliminate differences. METHODS: A sample of the
general population (n = 298) and two patient groups (rheuma-
toid arthritis, n = 27; cancer, n = 48) assessed the same 17 hypo-
thetical health states in an experimental setting. Patients did not
know that a description of their own health status was added to
the set of states. The ﬁrst and most elementary measurement
strategy consisted of ranking the health states, which can be
considered a step-by-step paired comparison task. In addition,
we used a multi-item visual analogue scale (VAS). This assess-
ment task can be considered as ranking supplemented with
adjusting the distances between the array of states in such a way
that the positions reﬂect the differences in preferences for these
states. The third measurement strategy was the time trade-off
(TTO) elicitation technique. RESULTS: Except for some moder-
ate divergence for certain health states, no overall differences
were found between patients and healthy people for the ranking
task or for the VAS. The TTO values, however, showed substan-
tially higher patient values (>0.20) for almost all moderate and
severe health states. This was more profound for the chronic
group of rheumatoid arthritis patients. CONCLUSIONS:
Patients’ assessment of health states are similar to assessments
of the general population when these are made by elementary
measurement methods. Therefore, valuation techniques based on
simple judgmental tasks such as ranking or discrete choices may
be better suited for deriving valid value-based health states.
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OBJECTIVES: The use of electronic patient reported outcomes
(ePRO) within clinical trials has grown rapidly with the increas-
ing acknowledgement by regulatory authorities that ePRO is an
acceptable method and one that directly addresses many of the
limitations of paper PROs. METHODS: A study of the charac-
teristics of ePRO use in clinical drug trials was undertaken to
understand the breath of therapeutic areas in which ePRO is
being used as well as to understand the dimensions affecting
compliance with ePRO. A dataset of 136 clinical trials was
analyzed by using ﬁelds that describe each protocol’s key
elements including ePRO instrument, Phase, Therapeutic Area,
Disorder and mean and median compliance broken down by
age deciles. RESULTS: The analysis determined that CNS (56
studies) and gastrointestinal disorders (21) represented 42% and
15% of ePRO use by the biopharmaceutical industry for this
dataset. Within CNS, ePRO was used heavily in depression
(24.3%), insomnia (9.6%) and anxiety protocols (8.1%).
Overall, ePRO was used in 16 different major disorders and
therapeutic areas. 57% of the time a named PRO instrument is
used electronically; the balance of the instruments is diaries or
symptom questionnaires which may not have undergone formal
validation. A sub-analysis of 8 pain studies representing 6% of
the studies showed that, with one exception, patients 46 years of
age and older are signiﬁcantly (means of 81.6% vs. 72.5%) more
compliant than study subjects younger than 46 years. The
median compliance for patients 66 of age and older was 87%.
CONCLUSIONS: This research shows that ePRO use within
clinical trials is both broad and deep; that patients can be highly
compliant; and that elderly patients are more compliant. Limita-
tions of this study include the clinical trials of this dataset which
can not be necessarily generalized as representative of all
ePRO use.
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OBJECTIVES: To demonstrate the signiﬁcance of patient-
reported outcomes (PROs) in facilitating market access using
evidence from deferasirox for iron-overload. METHODS:
Reviews of European reimbursement (NICE/French Transpar-
ency Commission) and regulatory authority (EMEA/CHMP)
guidance and opinions were performed. A PUBMED search was
implemented using PRO keywords and iron chelation therapy
(ICT). We considered the added value of deferasirox (oral-ICT)
demonstrated by PROs at various timepoints of the product
lifecycle. RESULTS: PROs in a product lifecycle can address
market access stakeholders’ concerns by demonstrating: 1)
disease/treatment burden on patients, and its impact on adher-
ence; 2) clinically meaningful outcomes from clinical trials and
beneﬁt to clinical practice; and 3) patient-perceived beneﬁts over
current treatments that may increase adherence, potentially
reducing health care costs. In our example, 28 studies were
identiﬁed. Medical importance and unmet needs were
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